249 related articles for article (PubMed ID: 25982836)
1. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative.
Laurens B; Constantinescu R; Freeman R; Gerhard A; Jellinger K; Jeromin A; Krismer F; Mollenhauer B; Schlossmacher MG; Shaw LM; Verbeek MM; Wenning GK; Winge K; Zhang J; Meissner WG
Neurobiol Dis; 2015 Aug; 80():29-41. PubMed ID: 25982836
[TBL] [Abstract][Full Text] [Related]
2. Potential clinical utility of multiple system atrophy biomarkers.
Jellinger KA
Expert Rev Neurother; 2017 Dec; 17(12):1189-1208. PubMed ID: 29023182
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
[TBL] [Abstract][Full Text] [Related]
4. Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy.
Tokutake T; Kasuga K; Tsukie T; Ishiguro T; Shimohata T; Onodera O; Ikeuchi T
Parkinsonism Relat Disord; 2022 Sep; 102():30-35. PubMed ID: 35933820
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis.
Cong S; Xiang C; Wang H; Cong S
J Neurol; 2021 Aug; 268(8):2703-2712. PubMed ID: 32162061
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
8. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.
Herbert MK; Eeftens JM; Aerts MB; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
Parkinsonism Relat Disord; 2014 Jan; 20(1):112-5. PubMed ID: 24075122
[TBL] [Abstract][Full Text] [Related]
9. The potential of phosphorylated α-synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy.
Abdul-Rahman T; Herrera-Calderón RE; Ahluwalia A; Wireko AA; Ferreira T; Tan JK; Wolfson M; Ghosh S; Horbas V; Garg V; Perveen A; Papadakis M; Ashraf GM; Alexiou A
CNS Neurosci Ther; 2024 Apr; 30(4):e14678. PubMed ID: 38572788
[TBL] [Abstract][Full Text] [Related]
10. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy.
Marques TM; Kuiperij HB; Bruinsma IB; van Rumund A; Aerts MB; Esselink RAJ; Bloem BR; Verbeek MM
Mol Neurobiol; 2017 Dec; 54(10):7736-7745. PubMed ID: 27844283
[TBL] [Abstract][Full Text] [Related]
13. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
[TBL] [Abstract][Full Text] [Related]
14. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.
Abdo WF; Bloem BR; Van Geel WJ; Esselink RA; Verbeek MM
Neurobiol Aging; 2007 May; 28(5):742-7. PubMed ID: 16678934
[TBL] [Abstract][Full Text] [Related]
15. Candidate biomarkers of multiple system atrophy in cerebrospinal fluid.
Zhang F; Chen J; Zhao L; Dong C
Rev Neurosci; 2014; 25(5):653-62. PubMed ID: 24867281
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein in erythrocyte membrane of patients with multiple system atrophy: A pilot study.
Liu G; Tian C; Gao L; Cao Z; Feng T
Parkinsonism Relat Disord; 2019 Mar; 60():105-110. PubMed ID: 30228038
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation.
Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
Neurosci Lett; 2011 Mar; 491(1):48-52. PubMed ID: 21215793
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study.
Singer W; Schmeichel AM; Sletten DM; Gehrking TL; Gehrking JA; Trejo-Lopez J; Suarez MD; Anderson JK; Bass PH; Lesnick TG; Low PA
Clin Auton Res; 2023 Dec; 33(6):635-645. PubMed ID: 37603107
[TBL] [Abstract][Full Text] [Related]
19. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy.
Santaella A; Kuiperij HB; van Rumund A; Esselink RAJ; Bloem BR; Verbeek MM
Parkinsonism Relat Disord; 2020 Jul; 76():80-84. PubMed ID: 32576494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
